Who are Cilostazol / Ginko Leaf Dried Ext.'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cilostazol-ginko-leaf-dried-ext.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cilostazol / Ginko Leaf Dried Ext. — Competitive Intelligence Brief

Cilostazol / Ginko Leaf Dried Ext. (Cilostazol / Ginko Leaf Dried Ext.) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combination / Herbal supplement combination. Area: Cardiovascular.

phase 3 Antiplatelet agent combination / Herbal supplement combination Phosphodiesterase-3 (cilostazol component); multiple targets including platelet aggregation pathways and vascular endothelial function (ginkgo component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Cilostazol / Ginko Leaf Dried Ext. (Cilostazol / Ginko Leaf Dried Ext.) — Seoul National University Bundang Hospital. This combination therapy inhibits platelet aggregation via phosphodiesterase-3 inhibition (cilostazol) while enhancing microcirculation and reducing blood viscosity through flavonoid and terpenoid components (ginkgo leaf extract).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cilostazol / Ginko Leaf Dried Ext. TARGET	Cilostazol / Ginko Leaf Dried Ext.	Seoul National University Bundang Hospital	phase 3	Antiplatelet agent combination / Herbal supplement combination	Phosphodiesterase-3 (cilostazol component); multiple targets including platelet aggregation pathways and vascular endothelial function (ginkgo component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combination / Herbal supplement combination class)

Seoul National University Bundang Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cilostazol / Ginko Leaf Dried Ext. — Competitive Intelligence Brief. https://druglandscape.com/ci/cilostazol-ginko-leaf-dried-ext. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab